Anixa Biosciences Investor Relations Material

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa's proprietary Somatichrome™ technology platform allows for the targeting of any antigen to the cell surface for presentation via a novel endogenous immune receptor known as the i-CAR (Immune Cell-Associated Recognition). This vector reutilization approach is designed to enable a best-in-class antibody replacement strategy. Anixa has established a diverse pipeline of product candidates in inactivated virus, toxoid and tumor antigens that includes several Phase II cancer vaccine candidate assets. Anixa's lead cancer vaccine asset is VGX-3100, the first antigen-specific cancer vaccine candidate focused on Merkel cell carcinoma.